BNY Mellon US Mid Cap Core Equity ETF (BKMC) has seen unusual trading volume, which is 23× higher than its average daily volume.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Among BKMC’s top positions, TechnipFMC has drawn fresh attention after multiple analysts, including Goldman Sachs and RBC Capital, reiterated bullish ratings and raised price targets, even as recent insider selling has created a more cautious tone around executive sentiment. Curtiss-Wright is under pressure as investors brace for a muted Q1 earnings catalyst, though Stifel has inched its price target higher while maintaining a Hold stance. Revolution Medicines has surged on strong Phase 3 data for its cancer drug daraxonrasib and a sharply upsized $1.5B equity offering, while Woodward is pulling back from record highs amid profit-taking and concerns about stretched valuation, and Royal Gold is benefiting from a new UBS Buy initiation that highlights its leverage to gold prices and expected volume-driven earnings growth.